Do you want to read an article? Please log in or register.
Biological Therapies: Effects of Proinflammatory Pathways and their Inhibition on the Myocardium of Rheumatoid Athritis Patients
Rheumatoid Arthritis
Related content
Psoriasis
Depressive symptoms, depression, and the effect of biologic therapy among patients in Psoriasis Longitudinal Assessment and Registry (PSOLAR)
J Am Acad Dermatol.
Strober B, Gooderham M, de Jong EMGJ, Kimball AB, Langley RG, Lakdawala N, Goyal K, Lawson F, Langholff W, Hopkins L, Fakharzadeh S, Srivastava B, Menter A
doi: 10.1016/j.jaad.2017.08.051.
Rheumatoid Arthritis
Long-Term Effectiveness of Adalimumab in Patients with Rheumatoid Arthritis: An Observational Analysis from the Corrona Rheumatoid Arthritis Registry
Rheumatol Ther.
Pappas DA, Kremer JM, Griffith J, Reed G, Salim B, Karki C, Garg V
doi: 10.1007/s40744-017-0077-z.
COMMENTED
Rheumatoid Arthritis
The effects of methotrexate and hydroxychloroquine combination therapy vs methotrexate monotherapy in early rheumatoid arthritis patients
Rheumatology (Oxford).
Schapink L, van den Ende CHM, Gevers LAHA, van Ede AE, den Broeder AA
doi: 10.1093/rheumatology/key275.
COMMENTED
Rheumatoid Arthritis
Effects of upadacitinib on patient-reported outcomes: results from SELECT-BEYOND, a phase 3 randomized trial in patients with rheumatoid arthritis and inadequate responses to biologic disease-modifying antirheumatic drugs
★ 3
Recommended and commented by
Dr Heino Prillwitz, Faculty Member
doi: 10.1186/s13075-019-2059-8.
Rheumatoid Arthritis
Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response
Ann Rheum Dis.
Fleischmann RM, Genovese MC, Enejosa JV, Mysler E, Bessette L, Peterfy C, Durez P, Ostor A, Li Y, Song IH
doi: 10.1136/annrheumdis-2019-215764.
Rheumatoid Arthritis
Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy: The FINCH 2 Randomized Clinical Trial
JAMA.
Genovese MC, Kalunian K, Gottenberg JE, Mozaffarian N, Bartok B, Matzkies F, Gao J, Guo Y, Tasset C, Sundy JS, de Vlam K, Walker D, Takeuchi T
doi: 10.1001/jama.2019.9055.
Rheumatoid Arthritis
Comparative effectiveness of tocilizumab versus TNF inhibitors as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis after the use of at least one biologic disease-modifying antirheumatic drug: analyses from the pan-European TOCERRA register collaboration
Ann Rheum Dis.
Lauper K, Nordström DC, Pavelka K, Hernández MV, Kvien TK, Kristianslund EK, Santos MJ, Rotar Ž, Iannone F, Codreanu C, Lukina G, Gale SL, Sarsour K, Luder Y, Courvoisier DS, Gabay C
doi: 10.1136/annrheumdis-
Rheumatoid Arthritis
Serious infection across biologic-treated patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis
Ann Rheum Dis.
Rutherford AI, Subesinghe S, Hyrich KL, Galloway JB
doi: 10.1136/annrheumdis-
Rheumatoid Arthritis
Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry study
Ann Rheum Dis.
Pappas DA, St John G, Etzel CJ, Fiore S, Blachley T, Kimura T, Punekar R, Emeanuru K, Choi J, Boklage S, Kremer JM
doi: 10.1136/annrheumdis-2020-217209.